It just clicks into place. It's fast and efficient.
The vaccine uses a novel nanoparticle platform (CoPoP) to deliver precise amounts of H5 and N1 proteins, achieving 100% protection in preclinical mouse trials against the deadly 2.3.4.4b H5N1 variant. Unlike current approved vaccines, this recombinant protein approach doesn't require eggs for manufacturing, potentially enabling faster production and adaptation to evolving bird flu strains resistant to existing vaccines.
- University at Buffalo vaccine achieved 100% protection against H5N1 variant 2.3.4.4b in mice
- Uses nanoparticle platform (CoPoP) instead of egg-based manufacturing
- H5 protein alone provided complete protection; adding N1 did not improve results
- Platform previously tested in COVID-19 clinical trials in South Korea and Philippines
University at Buffalo researchers have developed an experimental bird flu vaccine using a nanoparticle platform that demonstrated complete protection against H5N1 variant 2.3.4.4b in mice, offering a faster alternative to egg-based vaccine production.
Researchers at the University at Buffalo have engineered a bird flu vaccine that stopped the virus cold in mice—complete protection, no illness, no detectable infection in the lungs. The work, published this week in Cell Biomaterials, targets the H5N1 variant known as 2.3.4.4b, the same strain that has swept through wild bird populations and poultry flocks worldwide, and has already jumped to dairy cattle, house cats, sea lions, and other mammals.
What makes this vaccine different is how it's built. Instead of using the traditional approach—growing virus in chicken eggs and then killing or weakening it—the Buffalo team engineered a delivery system made of tiny spherical nanoparticles they call CoPoP. These microscopic containers are constructed from cobalt and porphyrin, wrapped in a phospholipid shell. The researchers then attached two key viral proteins to these particles: hemagglutinin, or H5, which the virus uses as a key to unlock and enter human cells, and neuraminidase, or N1, which acts like molecular scissors to help the virus spread once inside. The attachment works through a chemical tag that binds to the cobalt like a magnet clicking onto metal—fast, efficient, and scalable.
In the mouse trials, the team tested three formulations: H5 alone, N1 alone, and both proteins together. The results were striking. H5 by itself delivered complete protection. Mice vaccinated with H5 showed no signs of illness, no weight loss, and no virus detected in their lungs even after exposure to the lethal strain. N1 alone was less effective, providing roughly 70 percent protection with some animals still showing symptoms and viral presence. When both proteins were combined into what's called a bivalent vaccine, protection remained complete—but it did not exceed what H5 alone achieved. The finding underscores H5's central role in the immune response, though Jonathan Lovell, the study's lead author and a biomedical engineering professor at Buffalo, emphasizes that N1 antibodies still matter. They reduce how much virus replicates and how severe the illness becomes, which could prove crucial as the virus mutates and evolves.
Lovell has been refining this nanoparticle platform for more than a decade. It's not entirely untested in humans. A spinoff company he co-founded, POP Biotechnologies, partnered with a South Korean firm to run phase 2 and phase 3 clinical trials of a COVID-19 vaccine using the same CoPoP technology in South Korea and the Philippines. That real-world experience gives the bird flu work a foundation that many experimental vaccines lack.
The practical advantage of this approach is production speed. Current approved bird flu vaccines require eggs—millions of them—to grow the virus. That process takes months and creates bottlenecks when a new strain emerges and the world needs doses fast. The Buffalo vaccine is a recombinant protein vaccine, meaning it uses only the genetic instructions for H5 and N1, not the whole virus. No eggs needed. The researchers also added two immune-boosting compounds, QS-21 and a synthetic version of monophosphoryl lipid A, mixed directly into the nanoparticle shell to amplify the body's response.
Lovell calls the results "extremely encouraging," but he's careful about the timeline. The team plans more mouse work—testing different doses, vaccination schedules, and storage conditions. Human trials remain months or years away. Still, the work arrives at a moment when public health officials are increasingly anxious about bird flu's trajectory. The 2.3.4.4b variant has proven unusually good at jumping species barriers. A faster, more flexible vaccine platform could be the difference between containment and crisis if the virus ever gains sustained human-to-human transmission.
Citações Notáveis
The results thus far are extremely encouraging, but we obviously have a lot more work to do.— Jonathan Lovell, lead researcher, University at Buffalo
Because our vaccine does not require eggs in manufacturing, it is potentially a faster and more efficient way to protect humans and animals from deadly strains of bird flu.— Jonathan Lovell
A Conversa do Hearth Outra perspectiva sobre a história
Why does it matter that H5 alone worked just as well as H5 and N1 together? Doesn't that seem like a step backward?
It actually tells you something important about how the immune system fights this virus. H5 is the entry point—it's what lets the virus get inside your cells in the first place. If you can teach your body to recognize and block H5, you've stopped the infection before it starts. N1 is more about what happens after infection takes hold, so it's a secondary defense.
So N1 is less important?
Not less important—different. If H5 fails for some reason, N1 can still reduce how much damage the virus does. But in these mice, H5 was so effective that N1 didn't add extra protection on top. That's useful information. It means you might not need both proteins in every formulation.
The egg-free production sounds like the real breakthrough here. How much faster are we talking?
The source doesn't give exact timelines, but the principle is clear. Growing virus in eggs takes months. This platform uses genetic instructions to make just the proteins you need. You're not waiting for chickens to lay eggs, you're not growing live virus, you're not dealing with the biological variability of eggs. It's chemistry, not biology. That's inherently faster and more controllable.
Has this platform actually been tested in people before?
Yes, but for COVID. The same nanoparticle technology went through phase 2 and phase 3 trials in South Korea and the Philippines as a COVID vaccine candidate. It didn't become a mainstream vaccine, but it proved safe enough to advance that far. That's why Lovell can say this isn't starting from zero.
What's the next step?
More animal work. Different doses, different schedules, different storage conditions. They need to understand how long immunity lasts, whether you need boosters, whether the vaccine works in older animals or animals with compromised immune systems. Only after that would human trials even be possible.